A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

The CMS has opted not to move forward with a plan that would have extended Medicare coverage to obesity drugs for millions of ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

The benefits consultant Mercer has said that 44% of U.S. companies with 500 or more employees covered obesity drugs last year. Medicare does pay for drugs like Wegovy for patients who have heart ...

The recent decision by the Trump administration to halt a proposal aimed at expanding coverage for anti-obesity medications under Medicare and Medicaid has significant implications for millions of ...

President Trump's administration has made the decision not to cover highly-popular obesity treatments under the 2026 Medicare Advantage and Part D policies. One day after the Senate confirmed Dr ...